UNIVERSITY OF MINNESOTA

UNIVERSITY OF MINNESOTA logo
🇺🇸United States
Ownership
Private
Established
1851-01-01
Employees
10K
Market Cap
-
Website
http://www.umn.edu
globenewswire.com
·

SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial

Mirdametinib showed significant confirmed objective response rates and manageable safety profile in NF1-PN patients, achieving deep and durable tumor volume reductions and early, sustained improvements in pain and quality of life. New Drug and Marketing Authorization Applications are under review, with a U.S. PDUFA action date set for February 28, 2025.
cidrap.umn.edu
·

Africa CDC launches trial of smallpox drug for mpox

Northeast China study identifies emerging Yezo virus in 2% of 988 participants, with 18 infected showing symptoms like fever, headache, and gastrointestinal issues. Researchers urge vigilance in differentiating Yezo from other tick-borne pathogens.
clinicalleader.com
·

What Can We Learn From A Highly Diverse Observational Study Of 17000 Patients

Agendia's FLEX trial, enrolling over 17,000 diverse breast cancer patients, aims to study full genome profiling and clinical data for stages I-III. The study, designed for patient convenience and clinician access, includes racial and ethnic diversity, offering deeper genetic insights and fostering investigator-initiated sub-studies. Key learnings emphasize the importance of diverse patient recruitment, patient-centric design, and advanced data management for clinical trials.
nature.com
·

Droplet Hi-C enables scalable, single-cell profiling of chromatin architecture in ...

Detailed experimental protocols for Droplet Hi-C and Paired Hi-C, including fixation, in situ Hi-C, and single-cell sequencing library construction, are described. Data processing and analysis methods for Droplet Hi-C data, such as demultiplexing, mapping, and extracting single-cell contacts, are outlined. The article also covers the analysis of chromatin interactions, compartments, domains, loops, and multi-way interactions, as well as the identification of structural variations (SVs) and extrachromosomal DNA (ecDNA) candidates. Ethical approval for specimen collection is noted.
brief.umn.edu
·

October 9, 2024 - Brief

The Board of Regents will discuss healthcare workforce education, AI in higher education, and budget requests. MN Cup celebrates 20 years of fostering entrepreneurship. U of M researchers collaborate with local organizations to address health issues. The U of M Climate Adaptation Partnership provides climate data for communities. Research and Outreach Centers upgrade weather stations for local farmers. High school students enroll in U of M college courses. U of M Crookston hosts Indigenous Peoples Day events. UMD is recognized for high student voter turnout. UMR celebrates scholarship recipients and benefactors. Twin Cities campus features events on democracy, Homecoming, and family legacies at the U of M.
medicine.yale.edu
·

Peter Tebben Selected as Director of Yale Bone Center

Peter Tebben, MD, an adult and pediatric endocrinologist, has joined Yale School of Medicine as the new director of the Yale Bone Center, succeeding Karl Insogna, MD. Tebben will oversee the center and contribute to the Yale Center for X-Linked Hypophosphatemia. His expertise in metabolic bone disease and mineral metabolism aims to benefit patients across age groups. Tebben emphasizes the need for better therapies for rare bone diseases and improved osteoporosis management, continuing Insogna’s work in developing a fracture liaison service. Tebben plans to build on the center’s strong history of clinical care and research, ensuring its work continues through education and ongoing research.
neurologylive.com
·

Friday 5 — October 4, 2024

NeurologyLive®'s Friday 5 highlights advocacy in neurological care, spotlight on cardiomyopathy expert Forum Kamdar, 24-month data on cell therapy for Parkinson disease, neuropsychiatric symptom management in Parkinson disease, and an overview of Dravet syndrome.
twin-cities.umn.edu
·

U of M's Tech Comm sets record startups, launches new initiative to grow impact

The University of Minnesota launched 25 startups in fiscal 2024, surpassing previous records for the fourth consecutive year. This achievement aligns with the '25 by 2025' goal and the new 'Discover, Advance, Impact' initiative aiming to raise $40 million for tech transfer. The University has a 68% long-term success rate for its 260+ startups, with 73% located in Minnesota. Notable startups include Niron Magnetics, Jord BioScience, Stimdia Medical, Reflection Sciences, and Objective Biotechnology.
cbc.ca
·

These two men make a living by participating in clinical drug trials

A documentary, 'Bodies for Rent,' follows men who rely on clinical trials for income, highlighting the risks and financial incentives. It traces the shift from prisoner testing to poor people as subjects, and the ethical issues arising from financial motivations to downplay side effects.
biospace.com
·

Immusoft to Announce Positive Phase 1 Data for First Engineered B Cell Therapy in a Clinical Trial

ISP-001, a single-dose therapy, showed pharmacodynamic and functional improvements in a patient with MPS I over nine months, with no adverse events reported. The Phase 1 trial, supported by a $8 million award from CIRM, will present initial results on October 14, 2024. ISP-001's administration was well-tolerated and required no preconditioning, indicating potential for treating MPS I and other diseases.
© Copyright 2024. All Rights Reserved by MedPath